Lifecore Biomedical Key Executives
This section highlights Lifecore Biomedical's key executives, including their titles and compensation details.
Find Contacts at Lifecore Biomedical
(Showing 0 of )
Lifecore Biomedical Earnings
This section highlights Lifecore Biomedical's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2025 | 2025-04-03 | $-0.14 | $-0.19 |
| Read Transcript | Q2 | 2025 | 2025-01-02 | $-0.27 | $-0.25 |
| Read Transcript | Q1 | 2025 | 2024-10-04 | N/A | N/A |
| Read Transcript | Q4 | 2024 | 2024-08-27 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2023-08-31 | $-0.07 | $-0.89 |
| Read Transcript | Q3 | 2023 | 2023-06-01 | $-0.13 | $-0.22 |
| Read Transcript | Q2 | 2023 | 2023-03-17 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2022-10-06 | $-0.13 | $-0.32 |
Financial Statements
Access annual & quarterly financial statements for Lifecore Biomedical, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | May 26, 2024 | May 28, 2023 | May 29, 2022 | May 31, 2021 | May 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $128.26M | $103.27M | $185.79M | $544.16M | $590.37M |
| Cost of Revenue | $86.41M | $75.98M | $135.23M | $462.69M | $515.38M |
| Gross Profit | $41.85M | $27.29M | $50.55M | $81.47M | $74.99M |
| Gross Profit Ratio | 32.63% | 26.43% | 27.21% | 14.97% | 12.70% |
| Research and Development Expenses | $8.57M | $8.24M | $7.84M | $10.22M | $11.10M |
| General and Administrative Expenses | $- | $43.01M | $42.43M | $65.26M | $72.09M |
| Selling and Marketing Expenses | $- | $5.10K | $200.00K | $100.00K | $100.00K |
| Selling General and Administrative Expenses | $40.46M | $43.02M | $42.63M | $65.36M | $72.19M |
| Other Expenses | $- | $-729.00K | $3.30M | $-12.80M | $-4.39M |
| Operating Expenses | $49.04M | $51.26M | $50.47M | $75.59M | $83.29M |
| Cost and Expenses | $135.45M | $127.23M | $185.71M | $538.27M | $598.66M |
| Interest Income | $- | $68.00K | $81.00K | $48.00K | $103.00K |
| Interest Expense | $18.09M | $18.18M | $17.26M | $15.34M | $9.60M |
| Depreciation and Amortization | $8.86M | $10.30M | $7.10M | $8.61M | $18.30M |
| EBITDA | $35.60M | $-35.98M | $1.96M | $13.00M | $-7.16M |
| EBITDA Ratio | 27.76% | -34.84% | 1.06% | 2.39% | -1.21% |
| Operating Income | $-8.84M | $-26.08M | $3.46M | $-6.86M | $-8.30M |
| Operating Income Ratio | -6.90% | -25.26% | 1.86% | -1.26% | -1.41% |
| Total Other Income Expenses Net | $18.36M | $-42.13M | $-8.90M | $-20.96M | $-4.77M |
| Income Before Tax | $9.51M | $-68.70M | $-51.92M | $-40.47M | $-51.31M |
| Income Before Tax Ratio | 7.42% | -66.53% | -27.95% | -7.44% | -8.69% |
| Income Tax Expense | $183.00K | $301.00K | $-5.84M | $-7.80M | $-13.12M |
| Net Income | $12.01M | $-102.19M | $-46.08M | $-32.66M | $-38.19M |
| Net Income Ratio | 9.37% | -98.96% | -24.80% | -6.00% | -6.47% |
| EPS | $0.39 | $-3.41 | $-1.56 | $-1.12 | $-1.31 |
| EPS Diluted | $0.33 | $-3.41 | $-1.56 | $-1.12 | $-1.31 |
| Weighted Average Shares Outstanding | 30.47M | 29.96M | 29.47M | 29.29M | 29.16M |
| Weighted Average Shares Outstanding Diluted | 36.66M | 29.96M | 29.47M | 29.29M | 29.16M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | February 23, 2025 | November 24, 2024 | August 25, 2024 | May 26, 2024 | February 25, 2024 | November 26, 2023 | August 27, 2023 | May 28, 2023 | February 26, 2023 | November 27, 2022 | August 28, 2022 | May 29, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.15M | $32.56M | $24.70M | $37.89M | $35.70M | $30.15M | $24.52M | $31.55M | $26.54M | $21.86M | $43.35M | $47.63M | $53.07M | $129.49M | $128.79M | $139.83M | $137.78M | $130.90M | $135.64M | $156.13M |
| Cost of Revenue | $25.31M | $21.48M | $19.32M | $20.61M | $23.81M | $20.19M | $21.79M | $23.16M | $17.99M | $16.18M | $37.10M | $36.12M | $39.18M | $116.50M | $111.27M | $115.03M | $118.09M | $110.27M | $119.30M | $132.04M |
| Gross Profit | $9.85M | $11.08M | $5.39M | $17.27M | $11.89M | $9.96M | $2.73M | $8.39M | $8.55M | $5.68M | $6.25M | $11.51M | $13.89M | $12.99M | $17.52M | $24.80M | $19.69M | $20.64M | $16.35M | $24.09M |
| Gross Profit Ratio | 28.01% | 34.04% | 21.81% | 45.59% | 33.31% | 33.02% | 11.12% | 26.60% | 32.21% | 25.97% | 14.42% | 24.16% | 26.18% | 10.03% | 13.60% | 17.74% | 14.29% | 15.76% | 12.05% | 15.43% |
| Research and Development Expenses | $2.04M | $1.92M | $2.19M | $2.16M | $2.17M | $2.10M | $2.15M | $2.12M | $2.23M | $2.12M | $2.05M | $2.06M | $2.06M | $2.72M | $2.83M | $2.58M | $2.56M | $2.57M | $2.51M | $2.71M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $11.68M | $- | $- | $- | $15.42M | $- | $- | $- | $16.04M | $- | $- | $- | $16.39M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $5.10K | $- | $- | $- | $5.60K | $- | $- | $- | $100.00K | $- | $- | $- | $1.80M |
| Selling General and Administrative Expenses | $10.09M | $11.12M | $14.30M | $12.22M | $9.85M | $9.19M | $9.21M | $11.69M | $10.28M | $10.77M | $10.66M | $15.42M | $9.72M | $13.84M | $15.94M | $16.14M | $15.22M | $16.11M | $17.90M | $18.19M |
| Other Expenses | $6.74M | $- | $483.00K | $-1.10M | $-814.00K | $-967.00K | $-170.00K | $-318.00K | $2.57M | $- | $-180.00K | $5.81M | $454.00K | $79.00K | $109.00K | $46.00K | $72.00K | $-11.79M | $-21.00K | $-4.46M |
| Operating Expenses | $18.87M | $13.04M | $16.97M | $14.38M | $12.02M | $11.28M | $11.35M | $13.80M | $15.08M | $10.47M | $12.71M | $17.48M | $11.78M | $16.55M | $18.77M | $18.71M | $17.78M | $18.68M | $20.41M | $20.90M |
| Cost and Expenses | $37.45M | $34.52M | $36.29M | $35.00M | $35.83M | $31.48M | $33.15M | $36.96M | $33.07M | $26.65M | $49.81M | $53.60M | $50.96M | $133.05M | $130.03M | $133.75M | $135.88M | $128.94M | $139.71M | $152.94M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $15.00K | $22.00K | $16.00K | $15.00K | $15.00K | $20.00K | $19.00K | $27.00K | $17.00K | $13.00K | $10.00K | $8.00K | $6.00K |
| Interest Expense | $5.48M | $5.46M | $5.37M | $5.79M | $4.29M | $4.07M | $3.94M | $4.47M | $4.83M | $3.61M | $3.68M | $3.48M | $4.11M | $4.33M | $7.92M | $5.02M | $4.18M | $3.04M | $3.11M | $3.15M |
| Depreciation and Amortization | $2.08M | $2.04M | $1.99M | $1.39M | $4.44M | $2.21M | $2.17M | $2.18M | $3.21M | $2.94M | $3.95M | $2.90M | $2.83M | $5.23M | $5.05M | $4.57M | $4.40M | $4.29M | $5.10M | $5.04M |
| EBITDA | $-7.22M | $489.00K | $-8.89M | $4.64M | $2.11M | $880.00K | $-6.42M | $-26.92M | $-3.21M | $-2.65M | $19.00K | $-30.12M | $-443.00K | $-31.70M | $1.38M | $6.14M | $2.86M | $-8.67M | $-7.10M | $-12.41M |
| EBITDA Ratio | -20.54% | 1.50% | -36.00% | 12.24% | 5.91% | 2.92% | -26.16% | -85.34% | -12.11% | -12.12% | 0.04% | -63.24% | -0.83% | -24.48% | 1.07% | 4.39% | 2.08% | -6.62% | -5.23% | -7.95% |
| Operating Income | $-9.03M | $-1.96M | $-11.58M | $2.89M | $-124.00K | $-1.33M | $-8.62M | $-5.03M | $-6.53M | $-5.35M | $-6.46M | $-5.97M | $-3.75M | $-3.46M | $-3.81M | $1.23M | $-793.00K | $-1.47M | $-12.47M | $-13.11M |
| Operating Income Ratio | -25.68% | -6.02% | -46.89% | 7.62% | -0.35% | -4.40% | -35.17% | -15.93% | -24.61% | -24.48% | -14.89% | -12.54% | -7.07% | -2.67% | -2.96% | 0.88% | -0.58% | -1.12% | -9.19% | -8.40% |
| Total Other Income Expenses Net | $-5.75M | $-4.57M | $-4.67M | $-9.29M | $217.00K | $-65.00K | $-3.91M | $-28.55M | $-4.73M | $-3.85M | $-8.07M | $-1.15M | $-2.97M | $4.61M | $-6.54M | $-5.50M | $-730.00K | $-14.54M | $-2.84M | $-7.32M |
| Income Before Tax | $-14.78M | $-6.53M | $-16.25M | $-7.14M | $15.00M | $14.18M | $-12.52M | $-33.57M | $-11.26M | $-9.20M | $-11.35M | $-36.40M | $-7.38M | $-41.27M | $-11.59M | $-3.44M | $-5.71M | $-16.00M | $-15.31M | $-20.43M |
| Income Before Tax Ratio | -42.04% | -20.05% | -65.80% | -18.85% | 42.02% | 47.02% | -51.06% | -106.42% | -42.43% | -42.06% | -26.17% | -76.43% | -13.91% | -31.87% | -9.00% | -2.46% | -4.15% | -12.22% | -11.29% | -13.08% |
| Income Tax Expense | $-8.00K | $43.00K | $-25.00K | $-57.00K | $217.00K | $-65.00K | $88.00K | $223.00K | $70.00K | $4.00K | $4.00K | $-518.00K | $-276.00K | $-2.82M | $-2.11M | $-575.00K | $-217.00K | $-2.70M | $-4.31M | $-5.28M |
| Net Income | $-14.77M | $-6.57M | $-16.23M | $-7.08M | $15.63M | $14.22M | $-10.75M | $-36.13M | $-36.51M | $-12.81M | $-11.35M | $-36.47M | $-12.85M | $-38.44M | $-9.48M | $-2.87M | $-5.50M | $-13.30M | $-11.00M | $-15.15M |
| Net Income Ratio | -42.01% | -20.18% | -65.70% | -18.70% | 43.78% | 47.16% | -43.85% | -114.53% | -137.58% | -58.57% | -26.18% | -76.58% | -24.21% | -29.69% | -7.36% | -2.05% | -3.99% | -10.16% | -8.11% | -9.70% |
| EPS | $-0.47 | $-0.25 | $-0.53 | $-0.23 | $0.51 | $0.47 | $-0.35 | $-1.19 | $-1.20 | $-0.42 | $-0.38 | $-1.24 | $-0.45 | $-1.30 | $-0.32 | $-0.10 | $-0.19 | $-0.47 | $-0.38 | $-0.52 |
| EPS Diluted | $-0.47 | $-0.25 | $-0.53 | $-0.23 | $0.43 | $0.39 | $-0.35 | $-1.19 | $-1.20 | $-0.42 | $-0.38 | $-1.24 | $-0.44 | $-1.30 | $-0.32 | $-0.10 | $-0.19 | $-0.45 | $-0.38 | $-0.52 |
| Weighted Average Shares Outstanding | 37.02M | 34.36M | 30.86M | 30.56M | 30.49M | 30.46M | 30.40M | 30.32M | 30.30M | 30.30M | 29.58M | 29.51M | 28.86M | 29.47M | 29.36M | 29.33M | 29.30M | 28.34M | 28.95M | 29.14M |
| Weighted Average Shares Outstanding Diluted | 37.02M | 34.36M | 30.86M | 30.56M | 36.61M | 36.42M | 30.40M | 30.32M | 30.30M | 30.30M | 29.58M | 29.51M | 29.48M | 29.47M | 29.42M | 29.33M | 29.32M | 29.28M | 29.24M | 29.22M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | May 26, 2024 | May 28, 2023 | May 29, 2022 | May 31, 2021 | May 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $8.46M | $19.09M | $1.64M | $1.29M | $360.00K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $8.46M | $19.09M | $1.64M | $1.29M | $360.00K |
| Net Receivables | $31.15M | $29.02M | $38.31M | $41.43M | $76.21M |
| Inventory | $39.98M | $45.38M | $66.97M | $69.66M | $66.31M |
| Other Current Assets | $1.44M | $4.92M | $41.36M | $42.66M | $14.23M |
| Total Current Assets | $81.03M | $99.26M | $123.99M | $148.32M | $157.11M |
| Property Plant Equipment Net | $151.04M | $134.59M | $139.01M | $200.39M | $217.66M |
| Goodwill | $13.88M | $13.88M | $13.88M | $69.39M | $69.39M |
| Intangible Assets | $4.20M | $4.20M | $15.55M | $36.12M | $38.10M |
| Goodwill and Intangible Assets | $18.08M | $18.08M | $29.43M | $105.51M | $107.49M |
| Long Term Investments | $- | $-12.05M | $-10.59M | $45.10M | $56.90M |
| Tax Assets | $- | $12.05M | $10.59M | $30.34M | $27.46M |
| Other Non-Current Assets | $3.81M | $3.21M | $3.00M | $-26.72M | $-25.30M |
| Total Non-Current Assets | $172.93M | $155.89M | $171.45M | $354.60M | $384.21M |
| Other Assets | $19.74M | $- | $- | $- | $- |
| Total Assets | $273.70M | $255.15M | $295.44M | $502.92M | $541.31M |
| Account Payables | $16.33M | $22.10M | $12.95M | $16.30M | $51.65M |
| Short Term Debt | $4.91M | $1.85M | $142.55M | $30.60M | $93.38M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.11M | $4.05M | $919.00K | $1.13M | $352.00K |
| Other Current Liabilities | $15.52M | $15.34M | $20.16M | $54.99M | $19.01M |
| Total Current Liabilities | $38.87M | $38.78M | $79.41M | $101.89M | $164.39M |
| Long Term Debt | $125.45M | $110.77M | $105.24M | $174.30M | $127.74M |
| Deferred Revenue Non-Current | $4.70M | $103.75M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $20.29M | $373.00K | $232.00K | $6.14M | $13.59M |
| Other Non-Current Liabilities | $30.49M | $104.39M | $-94.94M | $23.96M | $4.55M |
| Total Non-Current Liabilities | $180.93M | $218.21M | $107.89M | $198.25M | $145.88M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $219.80M | $256.99M | $187.30M | $300.14M | $310.27M |
| Preferred Stock | $42.59M | $39.24M | $- | $- | $- |
| Common Stock | $30.00K | $30.00K | $30.00K | $29.00K | $29.00K |
| Retained Earnings | $-166.52M | $-176.22M | $-58.66M | $38.58M | $71.25M |
| Accumulated Other Comprehensive Income Loss | $- | $-39.24M | $-586.00K | $-1.36M | $-2.81M |
| Other Total Stockholders Equity | $177.81M | $176.66M | $167.35M | $165.53M | $162.58M |
| Total Stockholders Equity | $53.90M | $-1.84M | $108.14M | $202.78M | $231.04M |
| Total Equity | $53.90M | $-1.84M | $108.14M | $202.78M | $231.04M |
| Total Liabilities and Stockholders Equity | $273.70M | $255.15M | $295.44M | $502.92M | $541.31M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $273.70M | $255.15M | $295.44M | $502.92M | $541.31M |
| Total Investments | $-1 | $-12.05M | $-10.59M | $45.10M | $56.90M |
| Total Debt | $130.36M | $112.74M | $153.09M | $221.40M | $221.12M |
| Net Debt | $121.90M | $93.65M | $151.45M | $220.11M | $220.76M |
Balance Sheet Charts
| Breakdown | February 23, 2025 | November 24, 2024 | August 25, 2024 | May 26, 2024 | February 25, 2024 | November 26, 2023 | August 27, 2023 | May 28, 2023 | February 26, 2023 | November 27, 2022 | August 28, 2022 | May 29, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.42M | $9.46M | $5.52M | $8.46M | $3.07M | $3.22M | $8.64M | $19.09M | $2.95M | $6.83M | $4.22M | $1.64M | $1.85M | $1.09M | $1.45M | $1.29M | $2.25M | $2.49M | $589.00K | $360.00K |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $5.42M | $9.46M | $5.52M | $8.46M | $3.07M | $3.22M | $8.64M | $19.09M | $2.95M | $6.83M | $4.22M | $1.64M | $1.85M | $1.09M | $1.45M | $1.29M | $2.25M | $2.49M | $589.00K | $360.00K |
| Net Receivables | $19.36M | $20.18M | $25.14M | $31.15M | $31.45M | $30.20M | $26.62M | $29.02M | $32.37M | $35.69M | $40.93M | $48.17M | $49.56M | $65.28M | $61.96M | $41.43M | $69.58M | $66.55M | $65.03M | $76.21M |
| Inventory | $34.60M | $39.21M | $41.64M | $39.98M | $39.67M | $41.45M | $41.69M | $45.38M | $48.70M | $77.52M | $64.28M | $66.84M | $73.70M | $79.43M | $69.42M | $69.66M | $76.78M | $71.20M | $60.00M | $66.31M |
| Other Current Assets | $24.83M | $13.01M | $1.88M | $1.44M | $1.97M | $1.84M | $5.87M | $4.92M | $4.42M | $7.05M | $7.16M | $8.11M | $6.92M | $8.72M | $9.59M | $42.66M | $14.32M | $13.95M | $21.75M | $14.23M |
| Total Current Assets | $84.21M | $81.86M | $74.18M | $81.03M | $76.16M | $76.71M | $82.81M | $99.26M | $88.44M | $127.09M | $115.90M | $123.71M | $132.04M | $154.52M | $142.41M | $148.32M | $162.93M | $154.19M | $147.37M | $157.11M |
| Property Plant Equipment Net | $130.46M | $152.88M | $151.13M | $151.04M | $147.88M | $146.95M | $140.42M | $134.59M | $126.72M | $126.80M | $125.78M | $127.11M | $132.00M | $191.91M | $194.76M | $200.39M | $192.22M | $192.04M | $193.52M | $217.66M |
| Goodwill | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $33.92M | $37.33M | $69.39M | $69.39M | $69.39M | $69.39M | $69.39M | $69.39M |
| Intangible Assets | $4.20M | $4.20M | $4.20M | $4.20M | $4.20M | $4.20M | $4.20M | $4.20M | $4.40M | $8.69M | $15.28M | $10.10M | $24.58M | $35.13M | $35.62M | $36.12M | $36.62M | $37.11M | $37.61M | $38.10M |
| Goodwill and Intangible Assets | $18.08M | $18.08M | $18.08M | $18.08M | $18.08M | $18.08M | $18.08M | $18.08M | $18.28M | $22.57M | $29.16M | $23.98M | $58.49M | $72.46M | $105.01M | $105.51M | $106.00M | $106.50M | $107.00M | $107.49M |
| Long Term Investments | $- | $- | $- | $-1 | $- | $- | $- | $-12.05M | $- | $- | $- | $- | $- | $- | $- | $45.10M | $45.10M | $45.10M | $56.90M | $56.90M |
| Tax Assets | $- | $- | $- | $19.74M | $- | $- | $- | $12.05M | $- | $- | $- | $10.59M | $- | $- | $- | $30.34M | $- | $- | $- | $- |
| Other Non-Current Assets | $4.95M | $2.57M | $3.43M | $3.81M | $4.13M | $4.07M | $4.31M | $3.21M | $2.71M | $2.60M | $-1.74M | $3.00M | $3.05M | $3.24M | $3.44M | $-26.72M | $3.57M | $1.33M | $1.40M | $2.16M |
| Total Non-Current Assets | $153.48M | $173.53M | $172.64M | $192.67M | $170.08M | $169.10M | $162.81M | $155.89M | $147.71M | $151.98M | $153.20M | $164.68M | $193.54M | $267.60M | $303.21M | $354.60M | $346.90M | $344.97M | $358.81M | $384.21M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $237.69M | $255.39M | $246.82M | $273.70M | $246.24M | $245.82M | $245.62M | $255.15M | $236.15M | $279.07M | $269.10M | $288.39M | $325.58M | $422.12M | $445.62M | $502.92M | $509.82M | $499.16M | $506.18M | $541.31M |
| Account Payables | $7.41M | $14.97M | $18.01M | $16.33M | $15.69M | $19.02M | $15.69M | $22.10M | $14.76M | $27.97M | $16.37M | $12.95M | $20.01M | $59.10M | $46.35M | $16.30M | $56.32M | $60.89M | $50.72M | $51.65M |
| Short Term Debt | $4.90M | $4.89M | $4.91M | $9.04M | $9.09M | $3.16M | $3.22M | $1.85M | $1.46M | $151.97M | $152.61M | $147.57M | $44.95M | $44.99M | $36.05M | $30.60M | $45.03M | $91.97M | $84.03M | $93.38M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $937.00K | $654.00K | $2.11M | $3.23M | $8.25M | $8.36M | $4.05M | $2.71M | $731.00K | $803.00K | $919.00K | $1.61M | $1.16M | $1.22M | $1.13M | $1.59M | $644.00K | $477.00K | $352.00K |
| Other Current Liabilities | $8.28M | $14.50M | $16.95M | $11.39M | $8.80M | $9.82M | $16.41M | $15.34M | $18.75M | $15.03M | $9.18M | $15.37M | $23.49M | $17.02M | $20.03M | $54.99M | $22.40M | $20.40M | $18.50M | $19.01M |
| Total Current Liabilities | $31.12M | $35.29M | $40.52M | $38.87M | $36.81M | $40.25M | $35.41M | $38.78M | $37.67M | $195.70M | $178.96M | $176.81M | $90.06M | $122.26M | $103.65M | $101.89M | $125.35M | $173.91M | $153.73M | $164.39M |
| Long Term Debt | $1.44M | $126.45M | $131.95M | $125.45M | $121.34M | $118.30M | $116.59M | $110.77M | $125.48M | $9.00M | $9.45M | $9.98M | $89.94M | $138.40M | $140.91M | $190.25M | $169.48M | $104.21M | $116.94M | $127.74M |
| Deferred Revenue Non-Current | $- | $- | $4.79M | $4.70M | $300.00K | $321.30K | $4.59M | $103.75M | $- | $- | $-95.86M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $443.00K | $20.29M | $607.00K | $416.00K | $456.00K | $373.00K | $80.00K | $10.00K | $124.00K | $10.71M | $961.00K | $1.37M | $4.09M | $6.14M | $6.61M | $6.75M | $9.36M | $13.59M |
| Other Non-Current Liabilities | $157.72M | $33.88M | $29.61M | $30.49M | $28.05M | $44.18M | $62.02M | $104.39M | $38.71M | $201.00K | $199.00K | $190.00K | $544.00K | $3.89M | $3.10M | $8.00M | $3.76M | $5.36M | $5.00M | $4.55M |
| Total Non-Current Liabilities | $159.15M | $160.34M | $166.80M | $180.93M | $150.00M | $163.22M | $183.65M | $218.21M | $164.27M | $9.21M | $9.77M | $20.89M | $91.44M | $143.66M | $148.10M | $198.25M | $179.85M | $116.31M | $131.29M | $145.88M |
| Other Liabilities | $45.20M | $44.31M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $235.46M | $239.94M | $207.32M | $219.80M | $186.81M | $203.47M | $219.07M | $256.99M | $201.95M | $204.91M | $188.73M | $197.70M | $181.51M | $265.92M | $251.75M | $300.14M | $305.20M | $290.22M | $285.02M | $310.27M |
| Preferred Stock | $45.20M | $44.31M | $43.44M | $42.59M | $41.75M | $40.92M | $40.11M | $39.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $37.00K | $37.00K | $31.00K | $30.00K | $30.00K | $30.00K | $30.00K | $30.00K | $30.00K | $30.00K | $30.00K | $30.00K | $29.00K | $29.00K | $29.00K | $29.00K | $29.00K | $29.00K | $29.00K | $29.00K |
| Retained Earnings | $-204.09M | $-191.46M | $-182.75M | $-166.52M | $-159.44M | $-175.07M | $-189.29M | $-176.22M | $-140.09M | $-99.90M | $-87.45M | $-76.10M | $-22.19M | $-9.34M | $29.10M | $38.58M | $41.45M | $46.94M | $60.24M | $71.25M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-42.59M | $-41.75M | $-40.92M | $-40.11M | $-39.24M | $- | $- | $-286.00K | $-586.00K | $-712.00K | $-816.00K | $-992.00K | $-1.36M | $-1.72M | $-2.10M | $-2.50M | $-2.81M |
| Other Total Stockholders Equity | $161.09M | $162.56M | $135.34M | $177.81M | $177.10M | $176.46M | $175.70M | $176.66M | $174.27M | $174.04M | $168.07M | $167.35M | $166.94M | $166.33M | $165.72M | $165.53M | $164.87M | $164.07M | $163.39M | $162.58M |
| Total Stockholders Equity | $2.23M | $15.45M | $-3.94M | $53.90M | $59.43M | $42.34M | $26.55M | $-1.84M | $34.21M | $74.17M | $80.36M | $90.70M | $144.07M | $156.20M | $193.87M | $202.78M | $204.62M | $208.94M | $221.16M | $231.04M |
| Total Equity | $2.23M | $15.45M | $-3.94M | $53.90M | $59.43M | $42.34M | $26.55M | $-1.84M | $34.21M | $74.17M | $80.36M | $90.70M | $144.07M | $156.20M | $193.87M | $202.78M | $204.62M | $208.94M | $221.16M | $231.04M |
| Total Liabilities and Stockholders Equity | $237.69M | $255.39M | $246.82M | $273.70M | $246.24M | $245.82M | $245.62M | $255.15M | $236.15M | $279.07M | $269.10M | $288.39M | $325.58M | $422.12M | $445.62M | $502.92M | $509.82M | $499.16M | $506.18M | $541.31M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $237.69M | $255.39M | $246.82M | $273.70M | $246.24M | $245.82M | $245.62M | $255.15M | $236.15M | $279.07M | $269.10M | $288.39M | $325.58M | $422.12M | $445.62M | $502.92M | $509.82M | $499.16M | $506.18M | $541.31M |
| Total Investments | $- | $- | $- | $-1 | $- | $- | $- | $-12.05M | $- | $- | $- | $- | $- | $- | $- | $45.10M | $45.10M | $45.10M | $56.90M | $56.90M |
| Total Debt | $130.34M | $131.34M | $136.86M | $130.36M | $126.27M | $120.26M | $118.58M | $112.74M | $126.94M | $160.97M | $157.04M | $153.19M | $134.88M | $183.38M | $176.96M | $221.40M | $214.51M | $196.18M | $200.97M | $221.12M |
| Net Debt | $124.92M | $121.89M | $131.34M | $121.90M | $123.20M | $117.04M | $109.94M | $93.65M | $123.98M | $154.13M | $152.81M | $151.54M | $133.03M | $182.29M | $175.51M | $220.11M | $212.26M | $193.69M | $200.38M | $220.76M |
Annual Cash Flow
| Breakdown | May 26, 2024 | May 28, 2023 | May 29, 2022 | May 31, 2021 | May 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $9.33M | $-102.19M | $-97.24M | $-32.66M | $-38.19M |
| Depreciation and Amortization | $8.86M | $13.51M | $17.79M | $19.87M | $18.84M |
| Deferred Income Tax | $163.00K | $351.00K | $-6.88M | $-7.89M | $-5.44M |
| Stock Based Compensation | $6.20M | $3.61K | $2.64K | $3.31K | $2.38K |
| Change in Working Capital | $-3.85M | $22.07M | $-6.70M | $8.89M | $-27.66M |
| Accounts Receivables | $-2.39M | $12.19M | $-6.29M | $5.78M | $-6.64M |
| Inventory | $862.00K | $-13.82M | $-6.08M | $-3.35M | $-12.18M |
| Accounts Payables | $-6.68M | $16.09M | $9.34M | $-5.98M | $-1.25M |
| Other Working Capital | $4.36M | $7.62M | $-3.67M | $12.45M | $-7.59M |
| Other Non Cash Items | $-20.93M | $28.19M | $66.03M | $23.46M | $32.99M |
| Net Cash Provided by Operating Activities | $-217.00K | $-34.46M | $-24.40M | $15.02M | $-17.04M |
| Investments in Property Plant and Equipment | $-17.92M | $-20.76M | $-28.13M | $-23.77M | $-26.69M |
| Acquisitions Net | $- | $16.61M | $63.66M | $12.91M | $2.43M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $45.10M | $- | $- |
| Other Investing Activities | $- | $16.67M | $1.14M | $12.91M | $364.00K |
| Net Cash Used for Investing Activities | $-17.92M | $-4.15M | $81.77M | $-10.86M | $-23.89M |
| Debt Repayment | $2.75M | $3.12M | $-55.41M | $7.47M | $41.77M |
| Common Stock Issued | $- | $4.82M | $- | $- | $30.00K |
| Common Stock Repurchased | $-152.00K | $- | $-789.00K | $-405.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.76M | $31.76M | $-1.61M | $-10.89M | $-1.79M |
| Net Cash Used Provided by Financing Activities | $7.51M | $39.70M | $-57.02M | $-3.42M | $40.02M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-10.63M | $17.45M | $348.00K | $742.00K | $-912.00K |
| Cash at End of Period | $8.46M | $19.09M | $1.64M | $1.29M | $553.00K |
| Cash at Beginning of Period | $19.09M | $1.64M | $1.29M | $553.00K | $1.47M |
| Operating Cash Flow | $-217.00K | $-34.46M | $-24.40M | $15.02M | $-17.04M |
| Capital Expenditure | $-17.92M | $-20.76M | $-28.13M | $-23.77M | $-26.69M |
| Free Cash Flow | $-18.14M | $-55.22M | $-52.53M | $-8.75M | $-43.73M |
Cash Flow Charts
| Breakdown | February 23, 2025 | November 24, 2024 | August 25, 2024 | May 26, 2024 | February 25, 2024 | November 26, 2023 | August 27, 2023 | May 28, 2023 | February 26, 2023 | November 27, 2022 | August 28, 2022 | May 29, 2022 | February 28, 2022 | November 30, 2021 | August 31, 2021 | May 31, 2021 | February 28, 2021 | November 30, 2020 | August 31, 2020 | May 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-14.77M | $-6.57M | $-16.23M | $-7.09M | $14.79M | $14.24M | $-12.61M | $-38.20M | $-36.51M | $-12.81M | $-11.35M | $-35.88M | $-12.85M | $-38.44M | $-9.48M | $-2.87M | $-5.50M | $-13.30M | $-11.00M | $-15.15M |
| Depreciation and Amortization | $2.08M | $2.04M | $1.99M | $1.39M | $4.44M | $2.21M | $2.17M | $3.12M | $3.21M | $2.94M | $3.95M | $2.90M | $3.53M | $5.91M | $5.05M | $5.06M | $4.98M | $4.72M | $5.10M | $5.04M |
| Deferred Income Tax | $-9.00K | $9.00K | $-100.00K | $-64.00K | $191.00K | $-40.00K | $76.00K | $294.00K | $70.00K | $4.00K | $-17.00K | $-1.52M | $-508.00K | $-2.83M | $-2.14M | $-586.00K | $-237.00K | $-2.72M | $-4.35M | $2.44M |
| Stock Based Compensation | $2.55M | $3.37M | $2.42M | $1.60M | $1.49M | $1.58M | $1.53M | $816.00K | $903.00K | $1.11M | $785.00K | $680.00K | $622.00K | $686.00K | $620.00K | $776.00K | $797.00K | $895.00K | $892.00K | $538.00K |
| Change in Working Capital | $-1.32M | $-6.14M | $7.47M | $4.55M | $-4.78M | $586.00K | $-4.20M | $7.83M | $740.00K | $4.97M | $6.82M | $9.07M | $-19.91M | $-2.62M | $6.86M | $-155.00K | $-11.38M | $61.00K | $20.36M | $-26.27M |
| Accounts Receivables | $-6.62M | $- | $6.02M | $106.00K | $-1.29M | $-3.60M | $2.39M | $3.20M | $-3.54M | $5.25M | $7.24M | $1.39M | $-12.07M | $-3.46M | $8.00M | $-403.00K | $-3.48M | $-1.52M | $11.18M | $-6.44M |
| Inventory | $7.05M | $- | $-1.66M | $-309.00K | $1.78M | $244.00K | $-849.00K | $-372.00K | $-5.27M | $-12.16M | $2.56M | $5.95M | $-2.14M | $-10.02M | $248.00K | $7.12M | $-5.58M | $-11.20M | $6.31M | $748.00K |
| Accounts Payables | $-3.50M | $-2.84M | $3.63M | $-2.06M | $-356.00K | $-59.00K | $-4.20M | $4.68M | $-379.00K | $11.13M | $581.00K | $-3.71M | $-2.09M | $13.63M | $1.52M | $-12.35M | $-4.17M | $9.62M | $917.00K | $-13.04M |
| Other Working Capital | $1.75M | $-3.31M | $-517.00K | $6.81M | $-4.92M | $4.00M | $-1.54M | $320.00K | $9.93M | $765.00K | $-3.56M | $5.44M | $-3.61M | $-2.78M | $-2.90M | $5.49M | $1.85M | $3.16M | $1.95M | $-7.54M |
| Other Non Cash Items | $12.68M | $1.18M | $3.81M | $15.02M | $-7.55M | $-8.16M | $13.24M | $8.86M | $19.86M | $1.43M | $-3.42M | $27.64M | $8.98M | $32.16M | $-86.00K | $2.19M | $3.48M | $11.78M | $6.01M | $20.70M |
| Net Cash Provided by Operating Activities | $1.20M | $-6.11M | $-643.00K | $8.76M | $-1.66M | $1.01M | $-8.33M | $-17.29M | $-11.72M | $-2.35M | $-1.53M | $36.00K | $-20.13M | $-5.14M | $831.00K | $4.42M | $-7.86M | $1.44M | $17.02M | $-12.70M |
| Investments in Property Plant and Equipment | $-5.46M | $-2.47M | $-3.39M | $-2.64M | $-6.25M | $-3.98M | $-5.05M | $-8.44M | $-7.10M | $-3.85M | $-2.93M | $-9.60M | $-5.53M | $-5.10M | $-7.91M | $-12.39M | $-3.98M | $-2.78M | $-4.62M | $-4.57M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $944.00K | $12.53M | $- | $3.13M | $45.00K | $118.60M | $- | $1.08M | $28.00K | $- | $8.03M | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $45.10M | $- | $- | $- | $- | $- |
| Other Investing Activities | $7.00M | $- | $- | $- | $- | $- | $- | $1.01M | $- | $- | $- | $-9.84M | $-45.09M | $- | $1.08M | $28.00K | $- | $8.03M | $4.86M | $2.00K |
| Net Cash Used for Investing Activities | $1.54M | $-2.47M | $-3.39M | $-2.64M | $-6.25M | $-3.98M | $-5.05M | $-7.50M | $5.43M | $-3.85M | $206.00K | $-19.39M | $67.98M | $-5.10M | $38.27M | $-12.36M | $-3.98M | $5.25M | $232.00K | $-4.57M |
| Debt Repayment | $-6.23M | $-10.94M | $1.68M | $- | $2.80M | $-2.44M | $2.25M | $26.95M | $-31.76M | $3.95M | $3.97M | $20.07M | $-47.05M | $9.96M | $-41.39M | $-2.52M | $-94.03M | $-12.03M | $-16.43M | $-3.03M |
| Common Stock Issued | $17.00K | $- | $1.00K | $- | $- | $- | $724.00K | $- | $-178.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $-589.00K | $-53.00K | $- | $- | $- | $- | $- | $- | $- | $-271.00K | $-6.00K | $-84.00K | $-428.00K | $-108.00K | $- | $-215.00K | $-82.00K | $-37.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $-748.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-568.00K | $23.45M | $-588.00K | $-738.00K | $4.83M | $-12.00K | $1.43M | $-2.38M | $34.35M | $4.86M | $-67.00K | $-923.00K | $-37.00K | $-84.00K | $2.87M | $9.51M | $105.62M | $7.28M | $-512.00K | $18.09M |
| Net Cash Used Provided by Financing Activities | $-6.78M | $12.52M | $1.09M | $-738.00K | $7.76M | $-2.45M | $2.93M | $20.90M | $2.41M | $8.81M | $3.91M | $19.14M | $-47.09M | $9.88M | $-38.95M | $6.99M | $11.59M | $-4.97M | $-17.02M | $15.02M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.24M | $-1.85M | $- | $611.00K | $- | $2.49M | $- | $-472.00K | $- |
| Net Change in Cash | $-4.04M | $3.94M | $-2.94M | $5.39M | $-148.00K | $-5.42M | $-10.45M | $16.14M | $-3.88M | $2.61M | $2.58M | $-211.00K | $763.00K | $-356.00K | $152.00K | $-953.00K | $-243.00K | $1.71M | $229.00K | $-2.25M |
| Cash at End of Period | $5.42M | $9.46M | $5.52M | $8.46M | $3.07M | $3.22M | $8.64M | $19.09M | $2.95M | $6.83M | $4.22M | $1.64M | $1.85M | $1.09M | $1.45M | $1.29M | $2.25M | $2.49M | $782.00K | $553.00K |
| Cash at Beginning of Period | $9.46M | $5.52M | $8.46M | $3.07M | $3.22M | $8.64M | $19.09M | $2.95M | $6.83M | $4.22M | $1.64M | $1.85M | $1.09M | $1.45M | $1.29M | $2.25M | $2.49M | $782.00K | $553.00K | $2.80M |
| Operating Cash Flow | $1.20M | $-6.11M | $-643.00K | $8.76M | $-1.66M | $1.01M | $-8.33M | $-17.29M | $-11.72M | $-2.35M | $-1.53M | $36.00K | $-20.13M | $-5.14M | $831.00K | $4.42M | $-7.86M | $1.44M | $17.02M | $-12.70M |
| Capital Expenditure | $-5.46M | $-2.47M | $-3.39M | $-2.64M | $-6.25M | $-3.98M | $-5.05M | $-8.44M | $-7.10M | $-3.85M | $-2.93M | $-9.60M | $-5.53M | $-5.10M | $-7.91M | $-12.39M | $-3.98M | $-2.78M | $-4.62M | $-4.57M |
| Free Cash Flow | $-4.26M | $-8.58M | $-4.04M | $6.13M | $-7.91M | $-2.97M | $-13.38M | $-25.73M | $-18.82M | $-6.20M | $-4.46M | $-9.56M | $-25.66M | $-10.23M | $-7.08M | $-7.97M | $-11.83M | $-1.35M | $12.40M | $-17.27M |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
$6.76
Stock Price
$250.29M
Market Cap
524
Employees
Chaska, MN
Location
Revenue (FY 2024)
$128.26M
24.2% YoY
Net Income (FY 2024)
$12.01M
111.8% YoY
EPS (FY 2024)
$0.33
109.7% YoY
Free Cash Flow (FY 2024)
$-18.14M
67.2% YoY
Profitability
Gross Margin
32.6%
Net Margin
9.4%
ROE
22.3%
ROA
4.4%
Valuation
P/E Ratio
14.26
P/S Ratio
1.34
EV/EBITDA
8.23
Market Cap
$250.29M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-217.00K
99.4% YoY
Free Cash Flow
$-18.14M
67.2% YoY
Balance Sheet Summary
Total Assets
$273.70M
7.3% YoY
Total Debt
$130.36M
15.6% YoY
Shareholder Equity
$53.90M
2976.7% YoY
Dividend Overview
No Dividend Data
Lifecore Biomedical, Inc. doesn't currently pay dividends.
Lifecore Biomedical Dividends
Explore Lifecore Biomedical's dividend history, including dividend yield, payout ratio, and historical payments.
Lifecore Biomedical News
Read the latest news about Lifecore Biomedical, including recent articles, headlines, and updates.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Laughing Water Capital Top 5 Investments (Q1 2025)
Holding a meaningful cash position due to buyouts, providing optionality and safety amidst macro uncertainty, with plans to invest opportunistically. Lifecore Biomedical shows promise with strengthened balance sheet, improved sales force, and potential sale within 3 years, offering significant upside. NextNav's GPS technology investment faces short-term stock weakness but has positive FCC developments and strategic refinancing, indicating long-term potential.
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore's newly hired chief legal and administration officer. The RSU awards, stock option and PSU award were granted April 14, 2025, pursuant to an employment agreement between Lifecore and Mr. Salus, and as a material inducement to Mr. Salus joining Lifecore as its chief legal and administration officer.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore's Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Thomas (Tom) Salus as chief legal and administration officer and corporate secretary.
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2025 Earnings Conference Call April 3, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Fiscal 2025 Third Quarter Earnings Call. During the call, all participants will be in a listen-only mode.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences
CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LFCR.